This compound is a pharmaceutical intermediate used in the synthesis of lenacapavir. It is a polycyclic molecule containing multiple aromatic rings, ether linkages, and halogen substituents, with a carboxylic acid functional group.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 2001608-72-4
3-methanesulfonyl-3-methylbut-1-yne
pharmaceutical intermediate
N-Desmethylsulfonyl Lenacapavir
pharmaceutical intermediate
(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoic acid
pharmaceutical intermediate
1-Pyrrolidinecarboxylic acid, 2,2'-[[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)-1-piperidinyl]phenyl]-2,5-pyrrolidinediyl]bis(6-fluoro-1H-benzimidazole-5,2-diyl)]bis-, 1,1'-bis(1,1-dimethylethyl) ester, (2S,2'S)-
pharmaceutical intermediate
1-Benzyl 2-methyl (2S)-4-methylidenepyrrolidine-1,2-dicarboxylate
pharmaceutical intermediate
6-chloro-9-(beta-D-ribofuranosyl)-9H-purin-2-amine
pharmaceutical intermediate
1-(2'-O,4-C-Methylene-beta-D-ribofuranosyl)uridine
pharmaceutical intermediate
(1S,4S,5S,8S,9S,12S,13R,20S)-9,13-dimethyl-18,21-dioxa-17-azahexacyclo[11.8.0.01,20.04,12.05,9.015,19]henicosa-15(19),16-dien-8-ol
pharmaceutical intermediate
(1R,14E,18R,22R,26S,29S)-26-tert-butyl-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxylic acid
GAWSCEHDGCHIPM-CARGABRYSA-N
CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)O)OC3=NC4=CC=CC=C4N=C3C(/C=C/CO[C@@H]5CCC[C@H]5OC(=O)N1)(F)F
—